Conolidine’s analgesic effects stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors during the central anxious technique, conolidine modulates alternate molecular targets. A Science Innovations study located that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://shans466fui6.blog2news.com/profile